Tempus AI, Inc. posted revenue of $382.5 million for Q2 2026, a 22% year-over-year increase, while net income reached $5.6 million. This positive performance enabled the company to raise its 2026 revenue guidance, reflecting strong growth in oncology diagnostics.

Key Highlights

  • EPS came in at $-0.13, surpassing the consensus estimate of $-0.14.
  • Diagnostics revenue reached $289.3 million with a 31% year-over-year increase in oncology test volumes.
  • Full-year Adjusted EBITDA expected to be approximately $65 million.

Strong Q2 Performance

The earnings per share (EPS) came in at $-0.13, surpassing the consensus estimate of $-0.14. The performance demonstrates a strong rebound for the company, particularly following a challenging market year, as its shares have dipped 29.0% year-to-date. Highlighting the resilience of its business segments, Tempus credited growth in both Oncology Diagnostics and Data Licensing for the uptick in revenue.

A positive trajectory amid fluctuating market conditions may encourage investor confidence.

Key Drivers of Revenue Growth

The quarterly figures are bolstered by key advancements in Tempus’s offerings, particularly in oncology. The company reported a notable 31% year-over-year increase in oncology test volumes, boosting Diagnostics revenue to $289.3 million due to heightened demand. Revenue from Data and Applications surged 28%, totaling $93.2 million, with Insights contributing to a substantial 36% increase year-over-year.

Furthermore, the company completed a $460 million offering of convertible senior notes, which positions it favorably for future expansions, including the anticipated acquisition of Personalis for approximately $1.5 billion. Such high revenue figures paired with net income indicate a potentially transformative phase for the company.

Market Reactions and Share Performance

Despite this gain, the stock has experienced a decline of 29.0% year-to-date and 23.5% over the past month. Investors may be encouraged by the burgeoning demand in oncology services, as reflected in the increased test volumes and the successful launch of new technologies like the FDA-approved xT Tumor Only assay. As Tempus continues to leverage its advancements in artificial intelligence and precision medicine, the company's ability to capture market share will be critical in restoring investor confidence and improving share performance.

Looking Ahead: Increased Guidance

The expected full-year Adjusted EBITDA of approximately $65 million underscores the company's positive trajectory. Investors will keenly monitor the integration of this acquisition and its subsequent impact on the company's operational performance as the sector evolves.

Analysis based on the Form 8-K filed 30 July 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.